Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (10216)	5/27/1999 11:23:00 AM
From: Bluegreen	Read Replies (3) \| Respond to of 17367

How can you figure ANYTHING if you don't know the stratification of G scores? How can Murphy or anybody have a correct statement? SL, can you help us out here?

To: aknahow who wrote (10216)	5/27/1999 12:44:00 PM
From: jackie	Read Replies (2) \| Respond to of 17367

Yes, by all means we must include the 62 patients in evaluating these unblinded results. If we do, it clearly indicates the bpi is working as it reinforces the assumed mortality rates for untreated cases. Boiled down to the essentials ask yourself one question: Would you want your loved one to receive Neuprex under these circumstances or not? If the answer is yes, would your expectations of a successful outcome go up or down? Obviously, even with the untreated placebo cases mixed in, those in the study group enjoyed a much lower mortality rate. Which would mean, a rational decision on my earlier question would be, I want my loved one in a group in which only half are going to receive the drug. Furthermore, I would have a higher confidence in the survival of my child if they were in the study. I think this one is a no brainer. It will be interesting to see how the market reacts to the unblinded results. Jack